Interleukin genes and associations with colon and rectal cancer risk and overall survival

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 905-915

  Bondurant, Kristina L ^a   Lundgreen, Abbie ^b   Herrick, Jennifer S ^b   Kadlubar, Susan ^c   Wolff, Roger K ^b   Slattery, Martha L ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

colon cancer; inflammatory; interleukins; rectal cancer; single nucleotide polymorphisms

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; COLON CANCER; CONTROLLED STUDY; CXCR1 GENE; CXCR2 GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTERFERON GAMMA GENE; INTERLEUKIN 1 RECEPTOR GENE; INTERLEUKIN 10 GENE; INTERLEUKIN 15 GENE; INTERLEUKIN 17A GENE; INTERLEUKIN 1A GENE; INTERLEUKIN 1B GENE; INTERLEUKIN 3 GENE; INTERLEUKIN 4 GENE; INTERLEUKIN 6 RECEPTOR GENE; INTERLEUKIN 8 GENE; INTERLEUKIN GENE; MALE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BODY MASS INDEX; COLONIC NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-3; INTERLEUKIN-8; INTERLEUKINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; RECTAL NEOPLASMS; RISK; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84871397192     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27660     Document Type: Article

References (46)

1. Neuman MG,. Immune dysfunction in inflammatory bowel disease. Transl Res 2007; 149: 173-86. (Pubitemid 46442010)
2. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114 e5.
3. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK,. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-8.
4. Balding J, Livingstone WJ, Conroy J, et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm 2004; 13: 181-7. (Pubitemid 39093340)
5. Slattery ML, Wolff RK, Herrick JS, et al. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007; 18: 1095-105. (Pubitemid 47498159)
6. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
7. Lurje G, Husain H, Power DG, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010; 21: 78-86.
8. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-42.
9. Bioque G, Bouma G, Crusius JB, et al. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 105-10. (Pubitemid 26130230)
10. Queiroz DM, Oliveira AG, Saraiva IE, et al. Immune response and gene polymorphism profiles in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15: 353-8.
11. Graziano F, Ruzzo A, Canestrari E, et al. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009; 9: 78-84.
12. Lurje G, Hendifar AE, Schultheis AM, et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009; 19: 95-102.
13. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70. (Pubitemid 36020767)
14. Shen W, Durum SK,. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res 2010; 35: 940-6.
15. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3. (Pubitemid 44871953)
16. Oliver J, Rueda B, Lopez-Nevot MA, et al. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 977-81, 981.e1-2.
17. Cummings JR, Ahmad T, Geremia A, et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis 2007; 13: 1063-8. (Pubitemid 47402588)
18. Saraiva M, O'Garra A,. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-81.
19. Danese S, Mantovani A,. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010; 29: 3313-23.
20. Lee YS, Choi HB, Lee IK, et al. Association between interleukin-4R and TGF-beta1 gene polymorphisms and the risk of colorectal cancer in a Korean population. Colorectal Dis 2010; 12: 1208-12.
21. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 1997; 57: 75-80. (Pubitemid 27020333)
22. Slattery ML, Edwards S, Curtin K, et al. Physical activity and colorectal cancer. Am J Epidemiol 2003; 158: 214-24. (Pubitemid 36944414)
23. Edwards S, Slattery ML, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994; 140: 1020-8. (Pubitemid 24373007)
24. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007; 120: 656-63. (Pubitemid 44969038)
25. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 1831-6.
26. Samowitz WS, Curtin K, Ma KN, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597-602. (Pubitemid 34461615)
27. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
28. Slattery ML, Curtin K, Wolff RK, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009; 52: 1304-11.
29. Kuss O, McLerran D,. A note on the estimation of the multinomial logistic model with correlated responses in SAS. Comput Methods Programs Biomed 2007; 87: 262-9. (Pubitemid 47212598)
30. Nyholt DR,. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-9. (Pubitemid 38420107)
31. Burton P, Gurrin L, Sly P,. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 1998; 17: 1261-91. (Pubitemid 28274209)
32. Slattery ML, Lundgreen A, Bondurant KL, et al. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 2011; 32: 1660-7.
33. Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in the TGF-beta signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20: 57-69.
34. Slattery ML, Herrick JS, Bondurant KL, et al. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer 2012; 130: 2974-80.
35. Yamamoto-Furusho JK, Santiago-Hernandez JJ, Perez-Hernandez N, et al. Interleukin 1 beta (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol 2011; 45: 531-5.
36. Festen EA, Goyette P, Scott R, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804.
37. Andersen V, Ernst A, Christensen J, et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet 2010; 11: 82.
38. McGovern DP, Rotter JI, Mei L, et al. Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. Inflamm Bowel Dis 2009; 15: 883-9.
39. Aithal GP, Day CP, Leathart J, et al. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun 2001; 2: 44-7. (Pubitemid 33674869)
40. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560-6. (Pubitemid 36793036)
41. Theodoropoulos G, Papaconstantinou I, Felekouras E, et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006; 12: 5037-43. (Pubitemid 44323275)
42. Zhang W, Stoehlmacher J, Park DJ, et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005; 5: 124-31.
43. Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 2009; 20: 1739-51.
44. Cacev T, Radosevic S, Krizanac S, et al. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008; 29: 1572-80.
45. Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci USA 2005; 102: 2543-8. (Pubitemid 40279413)
46. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13: 635-8. (Pubitemid 39279773)